Literature DB >> 10527401

A susceptibility region for myasthenia gravis extending into the HLA-class I sector telomeric to HLA-C.

M Janer1, A Cowland, J Picard, D Campbell, P Pontarotti, J Newsom-Davis, M Bunce, K Welsh, A Demaine, A G Wilson, N Willcox.   

Abstract

We have analyzed a series of HLA region markers in 207 UK Caucasoids with early-onset myasthenia gravis (EOMG, onset before age 40), where there is a strong female bias. The well known associations with HLA-DR3 and -B8 have now proved to be significantly stronger in the 165 females than in the 42 males. In patients (of either sex) lacking -DR3, there was also a significant increase in HLA-DR2. Although the muscle weakness in EOMG is clearly mediated by autoantibodies, the associations are consistently stronger with HLA-B8 (in class I) than with HLADR3 (in class II), as confirmed here. We therefore typed 87-137 cases for polymorphisms at four loci in the intervening class III region, and also at three in the adjacent stretch of class I. At each locus, one allele tended to co-occur with HLA-B8 and showed strong and highly significant associations in the patients. There appeared to be a region of maximal susceptibility extending from HSP70 (in class III) past HLA-B and HLA-C at least 600 kb telomerically into the class I region, which is now being mapped in detail. Any candidate genes here that act shortly after puberty may allow more precise localization of susceptibility.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10527401     DOI: 10.1016/s0198-8859(99)00062-2

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  14 in total

1.  Pleiotropic effects of the 8.1 HLA haplotype in patients with autoimmune myasthenia gravis and thymus hyperplasia.

Authors:  Claire Vandiedonck; Geneviève Beaurain; Matthieu Giraud; Catherine Hue-Beauvais; Bruno Eymard; Christine Tranchant; Philippe Gajdos; Jean Dausset; Henri-Jean Garchon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-15       Impact factor: 11.205

2.  Granzyme B: evidence for a role in the origin of myasthenia gravis.

Authors:  L Casciola-Rosen; A Miagkov; K Nagaraju; F Askin; L Jacobson; A Rosen; D B Drachman
Journal:  J Neuroimmunol       Date:  2008-08-03       Impact factor: 3.478

3.  Risk for myasthenia gravis maps to a (151) Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08.

Authors:  Peter K Gregersen; Roman Kosoy; Annette T Lee; Janine Lamb; Jon Sussman; David McKee; Kim R Simpfendorfer; Ritva Pirskanen-Matell; Frederik Piehl; Qiang Pan-Hammarstrom; Jan J G M Verschuuren; Maarten J Titulaer; Erik H Niks; Alexander Marx; Philipp Ströbel; Björn Tackenberg; Michael Pütz; Angelina Maniaol; Ahmed Elsais; Chantal Tallaksen; Hanne F Harbo; Benedicte A Lie; Soumya Raychaudhuri; Paul I W de Bakker; Arthur Melms; Henri-Jean Garchon; Nicholas Willcox; Lennart Hammarstrom; Michael F Seldin
Journal:  Ann Neurol       Date:  2012-10-10       Impact factor: 10.422

4.  Differential estrogen receptor expression in autoimmune myasthenia gravis.

Authors:  Patrice Nancy; Sonia Berrih-Aknin
Journal:  Endocrinology       Date:  2005-01-20       Impact factor: 4.736

5.  Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases.

Authors:  John D Rioux; Philippe Goyette; Timothy J Vyse; Lennart Hammarström; Michelle M A Fernando; Todd Green; Philip L De Jager; Sylvain Foisy; Joanne Wang; Paul I W de Bakker; Stephen Leslie; Gilean McVean; Leonid Padyukov; Lars Alfredsson; Vito Annese; David A Hafler; Qiang Pan-Hammarström; Ritva Matell; Stephen J Sawcer; Alastair D Compston; Bruce A C Cree; Daniel B Mirel; Mark J Daly; Tim W Behrens; Lars Klareskog; Peter K Gregersen; Jorge R Oksenberg; Stephen L Hauser
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-21       Impact factor: 11.205

Review 6.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

Review 7.  The immunogenetics of neurological disease.

Authors:  Maneesh K Misra; Vincent Damotte; Jill A Hollenbach
Journal:  Immunology       Date:  2017-12-11       Impact factor: 7.397

8.  Genome-Wide Association Study of Late-Onset Myasthenia Gravis: Confirmation of TNFRSF11A and Identification of ZBTB10 and Three Distinct HLA Associations.

Authors:  Michael F Seldin; Omar K Alkhairy; Annette T Lee; Janine A Lamb; Jon Sussman; Ritva Pirskanen-Matell; Fredrik Piehl; Jan J G M Verschuuren; Anna Kostera-Pruszczyk; Piotr Szczudlik; David McKee; Angelina H Maniaol; Hanne F Harbo; Benedicte A Lie; Arthur Melms; Henri-Jean Garchon; Nicholas Willcox; Peter K Gregersen; Lennart Hammarstrom
Journal:  Mol Med       Date:  2015-11-10       Impact factor: 6.354

9.  Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis.

Authors:  J S Yi; A Guidon; S Sparks; R Osborne; V C Juel; J M Massey; D B Sanders; K J Weinhold; J T Guptill
Journal:  J Autoimmun       Date:  2013-12-28       Impact factor: 7.094

10.  Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population.

Authors:  Angelina H Maniaol; Ahmed Elsais; Åslaug R Lorentzen; Jone F Owe; Marte K Viken; Hanne Sæther; Siri T Flåm; Geir Bråthen; Margitta T Kampman; Rune Midgard; Marte Christensen; Anna Rognerud; Emilia Kerty; Nils Erik Gilhus; Chantal M E Tallaksen; Benedicte A Lie; Hanne F Harbo
Journal:  PLoS One       Date:  2012-05-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.